Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 51, 2016 - Issue 1
Submit an article Journal homepage
737
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists

Petra BajiDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary, Europe;CERGE-EI Fellow, Politických vězňů 936/7, 110 00 Praha 1-Nové Město, The Czech Republic, EuropeCorrespondence[email protected]
,
László GulácsiDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary, Europe
,
Barbara D. Lovász1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a, H-1083 Budapest, Hungary, Europe
,
Petra A. Golovics1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a, H-1083 Budapest, Hungary, Europe
,
Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary, Europe
,
Márta PéntekDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary, Europe;Department of Rheumatology, Flór Ferenc County Hospital, Semmelweis tér 1, H-2143 Kistarcsa, Hungary, Europe
,
Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary, Europe;Semmelweis University Doctoral School of Clinical Medicine, Üllői út 26, H-1085 Budapest, Hungary, Europe
&
Péter L. Lakatos1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a, H-1083 Budapest, Hungary, Europe
 show all
Pages 22-27 | Received 27 Mar 2015, Accepted 18 May 2015, Published online: 10 Jun 2015

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Peita L Graham-Clarke, Brett Hauber, Marco Boeri, Felice Leonardi, Russel T Burge, Maria Fernandez, Antje Tockhorn-Heidenreich & Sandra Florez. (2020) Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia. Patient Preference and Adherence 14, pages 1049-1064.
Read now
John Waller, Emma Sullivan, James Piercy, Christopher M Black & Sumesh Kachroo. (2017) Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference and Adherence 11, pages 519-530.
Read now
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B. Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Peter L. Lakatos & Valentin Brodszky. (2017) Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research 17:6, pages 597-606.
Read now
András Inotai, Christiaan P.J Prins, Marcell Csanádi, Dinko Vitezic, Catalin Codreanu & Zoltán Kaló. (2017) Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opinion on Biological Therapy 17:8, pages 915-926.
Read now
Dae Hyun Yoo. (2017) CT-P13 in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 13:7, pages 653-666.
Read now
Sean McConachie, Sheila M. Wilhelm & Pramodini B. Kale-Pradhan. (2017) Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. Expert Review of Clinical Pharmacology 10:4, pages 391-400.
Read now

Articles from other publishers (17)

Soon Cien Chong, Retha Rajah, Poh Lee Chow, Hsio Ching Tan, Chin Man Chong, Kar Yee Khor, Wan Ping Lee & Wan Ying Tan. (2022) Perspectives toward biosimilars among oncologists: A Malaysian survey. Journal of Oncology Pharmacy Practice, pages 107815522211047.
Crossref
Samantha Yun-Kai Poon, Jason C. Hsu, Yu Ko & Shao-Chin Chiang. (2021) Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan. Healthcare 9:11, pages 1600.
Crossref
Sabine Vogler, Peter Schneider, Martin Zuba, Reinhard Busse & Dimitra Panteli. (2021) Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Frontiers in Pharmacology 12.
Crossref
Louise C. Druedahl, Sofia Kälvemark Sporrong, Marco van de Weert, Marie Louise De Bruin, Hans Hoogland, Timo Minssen & Anna Birna Almarsdóttir. (2021) Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. BioDrugs 35:3, pages 351-361.
Crossref
Kati Sarnola, Merja Merikoski, Johanna Jyrkkä & Katri Hämeen-Anttila. (2020) Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open 10:5, pages e034183.
Crossref
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet & Peter L. Lakatos. (2019) Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry 26:2, pages 259-269.
Crossref
Vikas Soekhai, Esther W. de Bekker-Grob, Alan R. Ellis & Caroline M. Vass. (2018) Discrete Choice Experiments in Health Economics: Past, Present and Future. PharmacoEconomics 37:2, pages 201-226.
Crossref
Emily LeonardMichael WascovichSonia OskoueiPaula GurzDelesha Carpenter. (2019) Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. Journal of Managed Care & Specialty Pharmacy 25:1, pages 102-112.
Crossref
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto & Jorge A. Dias. (2019) Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. Journal of Pediatric Gastroenterology & Nutrition 68:1, pages 144-153.
Crossref
Joanna Sieczkowska-Golub, Monika Meglicka, Anna Plocek, Aleksandra BanaszkiewiczDorota Jarzębicka, Ewa Toporowska-Kowalska, Agnieszka GawronskaGrzegorz Oracz & Jaroslaw Kierkus. (2017) Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 65:3, pages 285-288.
Crossref
Till Uhlig & Guro L. Goll. (2017) Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology 56:suppl_4, pages iv49-iv62.
Crossref
László Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz & Márta Péntek. (2017) The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Advances in Therapy 34:5, pages 1128-1144.
Crossref
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky & Petra Baji. (2017) Access to biologicals in Crohn’s disease in ten European countries. World Journal of Gastroenterology 23:34, pages 6294.
Crossref
Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz & Péter L. Lakatos. (2016) Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues 10, pages 85-90.
Crossref
Filipe C. Araújo, João Gonçalves & João Eurico Fonseca. (2016) Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. Current Rheumatology Reports 18:8.
Crossref
Jürgen Braun & Alex Kudrin. (2016) Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 44:4, pages 257-266.
Crossref
Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay, Tore K Kvien, Josef Smolen, Yoshiya Tanaka & Gerd R Burmester. (2016) The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases 75:6, pages 974-982.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.